Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe and acarbose for nonalcoholic fatty liver disease
IRCT201109197590N1Phase 2Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- May 2011
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ezetimibe and acarbose in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Qazvin University of Medical Sciences. Started May 2011; status: completed.
02
Drugs
ezetimibeacarbose
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT201109197590N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201109197590N1.